Compare CVS Health Corp (CVS) vs Vanguard Tax Managed Fund FTSE Developed Markets ETF (VEA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Vanguard Tax Managed Fund FTSE Developed Markets ETF — how do they compare? CVS Health Corp trades at $87.13 (market cap $112.29B), while Vanguard Tax Managed Fund FTSE Developed Markets ETF trades at $70.21 (market cap $323.80B). The key difference: Vanguard Tax Managed Fund FTSE Developed Markets ETF is far larger — about 2.9× CVS Health Corp's market cap, and CVS Health Corp pays a 3.03% dividend while Vanguard Tax Managed Fund FTSE Developed Markets ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Vanguard Tax Managed Fund FTSE Developed Markets ETF for 131 Days on average.
| CVS | VEA | |
|---|---|---|
Market Cap | $112.29B | $323.80B |
Volume | 7,763,676 | 17,001,112 |
Sector | Health | — |
52-Week High | $110.60 | $73.79 |
52-Week Low | $70.08 | $58.90 |
Typical Hold Time | 83 Days | 131 Days |
Enterprise Value | $174.64B | — |
Dividend Yield | 3.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.95, up 1.76% on the day, with a bullish technical signal and strong analyst support. Recent earnings beats in Q1 and Q2 2026, alongside steady revenue growth to $402.07B in 2025, highlight operational strength. The stock's valuation appears attractive with a P/E of 23.17 and P/S of 0.27, while a consensus price target of $111.20 suggests significant upside potential. Positive news includes Aetna's 2027 Medicare plan enhancements and a declared quarterly dividend.
The outlook for CVS remains positive, driven by earnings momentum and strategic initiatives in healthcare services. Key risks include reimbursement pressures and regulatory scrutiny, but Wall Street's 85% buy rating and institutional interest underscore confidence. Investors should weigh the stock's growth prospects against margin volatility and debt levels, with the current price offering a favorable entry point relative to targets.
VEA trades at $70.19, down 0.1% with a bearish technical signal. The ETF shows mixed institutional activity with some firms increasing positions while others reduced holdings. Recent news highlights VEA's competitive advantages including a low 0.03% expense ratio and higher dividend yield compared to peers. Technical indicators show oversold conditions with RSI at 28.4, suggesting potential for near-term bounce.
The outlook remains cautious given bearish technical momentum, though the fund's cost efficiency and developed market exposure provide long-term value. Key risks include global market volatility and currency fluctuations. Investors should monitor institutional flow trends and global economic developments for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Vanguard Tax Managed Fund FTSE Developed Markets ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Developed All Cap ex US Index, a market-capitalization-weighted index that is made up of approximately 4022 common stocks of large-, mid-, and small-cap companies located in Canada and the major markets of Europe and the Pacific region. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VEA →
